Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023

Author: Benzinga Insights | January 31, 2023 11:00am

Upgrades

For Silvercorp Metals Inc (AMEX:SVM), Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Silvercorp Metals shows a 52-week-high of $4.20 and a 52-week-low of $1.99. Moreover, at the end of the last trading period, the closing price was at $3.31.

For LyondellBasell Industries NV (NYSE:LYB), Atlantic Equities upgraded the previous rating of Neutral to Overweight. For the third quarter, LyondellBasell Industries had an EPS of $1.96, compared to year-ago quarter EPS of $5.25. The stock has a 52-week-high of $117.22 and a 52-week-low of $71.46. At the end of the last trading period, LyondellBasell Industries closed at $94.46.

According to Goldman Sachs, the prior rating for Inter & Co Inc (NASDAQ:INTR) was changed from Neutral to Buy. At the moment, the stock has a 52-week-high of $4.63 and a 52-week-low of $1.72. Inter & Co closed at $2.47 at the end of the last trading period.

According to William Blair, the prior rating for FibroGen Inc (NASDAQ:FGEN) was changed from Market Perform to Outperform. FibroGen earned $0.98 in the third quarter, compared to $0.54 in the year-ago quarter. The stock has a 52-week-high of $22.63 and a 52-week-low of $7.81. At the end of the last trading period, FibroGen closed at $21.59.

See all analyst ratings upgrades.

Downgrades

For Sierra Bancorp (NASDAQ:BSRR), Hovde Group downgraded the previous rating of Outperform to Market Perform. In the fourth quarter, Sierra Bancorp showed an EPS of $0.47, compared to $0.63 from the year-ago quarter. At the moment, the stock has a 52-week-high of $27.24 and a 52-week-low of $19.62. Sierra Bancorp closed at $21.32 at the end of the last trading period.

For HomeStreet Inc (NASDAQ:HMST), Keefe, Bruyette & Woods downgraded the previous rating of Outperform to Market Perform. HomeStreet earned $0.45 in the fourth quarter, compared to $1.43 in the year-ago quarter. At the moment, the stock has a 52-week-high of $52.95 and a 52-week-low of $22.44. HomeStreet closed at $26.82 at the end of the last trading period.

For Q2 Holdings Inc (NYSE:QTWO), Baird downgraded the previous rating of Outperform to Neutral. In the third quarter, Q2 Holdings showed an EPS of $0.10, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $67.77 and a 52-week-low of $20.93. At the end of the last trading period, Q2 Holdings closed at $32.04.

For Bank of America Corp (NYSE:BAC), Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the fourth quarter, Bank of America showed an EPS of $0.85, compared to $0.82 from the year-ago quarter. The current stock performance of Bank of America shows a 52-week-high of $50.11 and a 52-week-low of $29.31. Moreover, at the end of the last trading period, the closing price was at $35.30.

For Eastern Bankshares Inc (NASDAQ:EBC), JP Morgan downgraded the previous rating of Neutral to Underweight. For the fourth quarter, Eastern Bankshares had an EPS of $0.31, compared to year-ago quarter EPS of $0.26. The current stock performance of Eastern Bankshares shows a 52-week-high of $22.35 and a 52-week-low of $15.25. Moreover, at the end of the last trading period, the closing price was at $15.65.

For Invitae Corp (NYSE:NVTA), Goldman Sachs downgraded the previous rating of Neutral to Sell. NoneThe current stock performance of Invitae shows a 52-week-high of $12.04 and a 52-week-low of $1.67. Moreover, at the end of the last trading period, the closing price was at $2.48.

See all analyst ratings downgrades.

Initiations

Craig-Hallum initiated coverage on Xometry Inc (NASDAQ:XMTR) with a Buy rating. The price target for Xometry is set to $48.00. For the third quarter, Xometry had an EPS of $0.11, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $64.35 and a 52-week-low of $26.61. Xometry closed at $32.66 at the end of the last trading period.

For Cutera Inc (NASDAQ:CUTR), William Blair initiated coverage, by setting the current rating at Market Perform. NoneThe current stock performance of Cutera shows a 52-week-high of $74.38 and a 52-week-low of $26.52. Moreover, at the end of the last trading period, the closing price was at $33.79.

Wedbush initiated coverage on ARS Pharmaceuticals Inc (NASDAQ:SPRY) with an Outperform rating. The price target for ARS Pharmaceuticals is set to $10.00. At the moment, the stock has a 52-week-high of $9.17 and a 52-week-low of $4.25. ARS Pharmaceuticals closed at $6.34 at the end of the last trading period.

Zacks Investment Research initiated coverage on Expion360 Inc (NASDAQ:XPON) with a Buy rating. The price target for Expion360 is set to $4.25. In the third quarter, Expion360 showed an EPS of $0.19, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.29 and a 52-week-low of $0.90. Expion360 closed at $2.21 at the end of the last trading period.

Piper Sandler initiated coverage on Incyte Corp (NASDAQ:INCY) with an Overweight rating. The price target for Incyte is set to $100.00. Incyte earned $0.60 in the third quarter, compared to $1.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $86.29 and a 52-week-low of $65.07. Incyte closed at $83.65 at the end of the last trading period.

With a Buy rating, EF Hutton initiated coverage on Onfolio Holdings Inc (NASDAQ:ONFO). The price target seems to have been set at $3.00 for Onfolio Holdings. In the third quarter, Onfolio Holdings showed an EPS of $0.31, compared to $0.30 from the year-ago quarter.

With a Buy rating, EF Hutton initiated coverage on Xencor Inc (NASDAQ:XNCR). The price target seems to have been set at $42.00 for Xencor. Xencor earned $0.55 in the third quarter, compared to $0.69 in the year-ago quarter. The stock has a 52-week-high of $35.92 and a 52-week-low of $19.36. At the end of the last trading period, Xencor closed at $31.70.

Stifel initiated coverage on Kura Oncology Inc (NASDAQ:KURA) with a Buy rating. The price target for Kura Oncology is set to $25.00. For the third quarter, Kura Oncology had an EPS of $0.53, compared to year-ago quarter EPS of $0.50. At the moment, the stock has a 52-week-high of $19.93 and a 52-week-low of $10.41. Kura Oncology closed at $13.17 at the end of the last trading period.

Stifel initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ:SNDX) with a Buy rating. The price target for Syndax Pharmaceuticals is set to $37.00. In the third quarter, Syndax Pharmaceuticals showed an EPS of $0.58, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $28.90 and a 52-week-low of $13.27. Syndax Pharmaceuticals closed at $27.09 at the end of the last trading period.

See all analyst ratings initiations.

Posted In: BAC BSRR CUTR EBC FGEN HMST INCY INTR KURA LYB NVTA ONFO QTWO SNDX SPRY SVM XMTR XNCR XPON

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist